Approvals· August 31, 2026 · 18 min read
Stelara's Pediatric UC License Does Not Write Wezlana Pediatric IBD Substitution
By Ran Chen#Biosimilars#Interchangeability#Purple Book
Topic
Interchangeability
FDA interchangeability, pharmacy substitution, state-law boundaries, and what the designation does and does not mean commercially.
Biosimilars· August 17, 2026 · 18 min read
FDA Biosimilar Device Guidance: Presentations That Are Not Interchangeable
By Ran Chen#Biosimilars#Interchangeability#Purple Book
Specialty· August 15, 2026 · 26 min read
Hidradenitis Suppurativa Access: Adalimumab Spread, Biologics, & Oral JAKs
By Ran Chen#Dermatology#Biosimilars#Interchangeability
Pricing & Access· August 13, 2026 · 22 min read
IBD Treatment Access (2026): Stelara & Humira Biosimilars Meet IL-23
Biosimilars· June 29, 2026 · 18 min read
Soliris Biosimilar Cliff: NMOSD Exclusivity Expiry and Payer Step Edits
By Ran Chen#Biosimilars#Interchangeability#Payer Policy
Biosimilars· June 21, 2026 · 6 min read
Soliris NMOSD Exclusivity Expiration: Skinny Label & REMS Barriers for Bkemv
Biosimilars· June 16, 2026 · 11 min read
Interchangeable biosimilars in the Purple Book: 46 products, 12 reference biologics
By Ran Chen#Biosimilars#Interchangeability#Purple Book
Biosimilars· June 7, 2026 · 8 min read
Langlara insulin glargine biosimilar: interchangeable Lantus, formulary, and switching
Biosimilars· June 1, 2026 · 12 min read
FDA biosimilar interchangeability without switching studies: the 2026 pathway
By Ran Chen#Biosimilars#Interchangeability#FDA Approval
Biosimilars· May 31, 2026 · 12 min read
Interchangeable biosimilar substitution notices and state-law workflow
By Ran Chen#Biosimilars#Interchangeability#Payer Policy